MedTech CFO consulting services to Cognito, NeuroElectrics.

Led S-1 IPO readiness, built financial team, managed banking activities. Currently completing $60M C round and RIF restructuring. Focused on Alzheimer's ph3.

Successful IPO for Berlin/NYC based mental health company. Led public company finance execution and built the team and public company infrastructure and street presence.Key Accomplishmentso Core team member responsible for $259 million Nasdaq IPO in June 2021, market cap $2.5Bo Managed complexities of platform structure with varied ownership of 15 mental health companies, across Germany, Netherlands, US, and UKo Led global finance functions across audit and tax, MSAs and transfer pricing across the platformo Raised $600 million across Series C, D, and IPOo Integrated financial operations for multiple acquisitionso Opened NYC office. 25-person finance team across the US, UK, and Germanyo Led IR, with 12 covering analystso Architect of $175 million asset-based debt facility with Hercules

Led rare disease start-up through a reverse merger/ US IPO in 2018 and built the finance function. Lead asset in cystic fibrosis phase 2 clinical trials.Key Accomplishmentso Led $100 million in two follow-on financings/ATMo Managed merger tail through many finance and legal challengeso Opened Boston HQ office, recruited accounting, finance and IR teams in Boston and Tel- Aviv, successfully implementing new systems, audits, processes

TSX/Nasdaq listed; led global financial ops and IR for this commercial resins and clinical stage plasma therapeutics company, Split time between Montreal, Cambridge UK and Boston offices. Company restructured into a newco, Liminal Biosciences following my departure.Key Accomplishmentso Raised $170 million with institutional investorso Led transition from the TSX to Nasdaq

Nasdaq autologous skin therapy Phase 2 clinical stage biotech.

Nasdaq Phase 3 oncology trial missed primary endpoint; led to dissolution.

Pre-IPO MedTech hospital pharmacy automation company. S1 drafted, remained private.

Nasdaq RNAi clinical focus, exit to Merck.

Nasdaq nasal delivery with multiple phase 2 clinical programs/collaborations.

Nasdaq listed, FDA approval of Campath and Clorfarabine. Millennium strategic collaboration, exit to Genzyme in 2005.